{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:48:13Z","timestamp":1790534893170,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,5,5]],"date-time":"2016-05-05T00:00:00Z","timestamp":1462406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1053\/j.ajkd.2016.04.011","type":"journal-article","created":{"date-parts":[[2016,6,3]],"date-time":"2016-06-03T14:06:00Z","timestamp":1464962760000},"page":"591-598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis"],"prefix":"10.1053","volume":"68","author":[{"given":"Kevin","family":"Quach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyubov","family":"Lvtvyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Baigent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Bueti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit X.","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel","family":"Hawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Braden","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian G.","family":"Rabbat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Wald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1053\/j.ajkd.2016.04.011_bib1","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1093\/ndt\/gfq781","article-title":"Global variation in renal replacement therapy for end-stage renal disease","volume":"26","author":"Caskey","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"1 suppl 1","key":"10.1053\/j.ajkd.2016.04.011_bib2","first-page":"Svii","article-title":"US Renal Data System 2014 Annual Data Report: epidemiology of kidney disease in\u00a0the\u00a0United States","volume":"66","author":"Saran","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2016.04.011_bib3","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/ki.1995.132","article-title":"Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors","volume":"47","author":"Harnett","year":"1995","journal-title":"Kidney Int"},{"issue":"7","key":"10.1053\/j.ajkd.2016.04.011_bib4","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1006\/jmcc.1994.1098","article-title":"Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone","volume":"26","author":"Brilla","year":"1994","journal-title":"J\u00a0Mol Cell Cardiol"},{"issue":"3","key":"10.1053\/j.ajkd.2016.04.011_bib5","doi-asserted-by":"crossref","first-page":"12A","DOI":"10.1016\/0002-9149(93)90239-9","article-title":"Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension","volume":"71","author":"Brilla","year":"1993","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1053\/j.ajkd.2016.04.011_bib6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/eurheartj\/ehn543","article-title":"Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials","volume":"30","author":"Ezekowitz","year":"2009","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1053\/j.ajkd.2016.04.011_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1053\/j.ajkd.2016.04.011_bib8","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2016.04.011_bib9","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2016.04.011_bib10","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"3","key":"10.1053\/j.ajkd.2016.04.011_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controll Clin Trials"},{"key":"10.1053\/j.ajkd.2016.04.011_bib12","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014."},{"issue":"2","key":"10.1053\/j.ajkd.2016.04.011_bib13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jclinepi.2012.01.006","article-title":"GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"2","key":"10.1053\/j.ajkd.2016.04.011_bib14","doi-asserted-by":"crossref","first-page":"e57132","DOI":"10.1371\/journal.pone.0057132","article-title":"Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers","volume":"8","author":"Akl","year":"2013","journal-title":"PloS One"},{"issue":"6","key":"10.1053\/j.ajkd.2016.04.011_bib15","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jacc.2013.09.056","article-title":"Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients","volume":"63","author":"Matsumoto","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1053\/j.ajkd.2016.04.011_bib16","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1681\/ASN.2013030273","article-title":"Long-term effects of spironolactone in peritoneal dialysis patients","volume":"25","author":"Ito","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2016.04.011_bib17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.7326\/M13-2886","article-title":"Random-effects meta-analysis of inconsistent effects: a time for change","volume":"160","author":"Cornell","year":"2014","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1053\/j.ajkd.2016.04.011_bib18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.ajkd.2005.03.005","article-title":"Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients","volume":"46","author":"Gross","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2016.04.011_bib19","first-page":"507","article-title":"A\u00a0prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis","volume":"23","author":"Taheri","year":"2012","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"3","key":"10.1053\/j.ajkd.2016.04.011_bib20","first-page":"392","article-title":"Spironolactone in chronic hemodialysis patients improves cardiac function","volume":"20","author":"Taheri","year":"2009","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"8","key":"10.1053\/j.ajkd.2016.04.011_bib21","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2215\/CJN.09421209","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients","volume":"5","author":"Vukusich","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2016.04.011_bib22","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.2215\/CJN.12371214","article-title":"The safety of eplerenone in hemodialysis patients: a noninferiority randomized controlled trial","volume":"10","author":"Walsh","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2016.04.011_bib23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/1744-9987.12219","article-title":"Randomized, double-blind, placebo-controlled trial of spironolactone for hypokalemia in continuous ambulatory peritoneal dialysis patients","volume":"19","author":"Yongsiri","year":"2015","journal-title":"Ther Apher Dial"},{"issue":"9","key":"10.1053\/j.ajkd.2016.04.011_bib24","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/jch.12374","article-title":"Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study","volume":"16","author":"Ni","year":"2014","journal-title":"J\u00a0Clin Hypertens"},{"issue":"5","key":"10.1053\/j.ajkd.2016.04.011_bib25","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1681\/ASN.2013030273","article-title":"Long-term effects of spironolactone in peritoneal dialysis patients","volume":"25","author":"Ito","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2016.04.011_bib26","doi-asserted-by":"crossref","first-page":"e25491","DOI":"10.1371\/journal.pone.0025491","article-title":"The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis\u2013a simulation study","volume":"6","author":"Thorlund","year":"2011","journal-title":"PloS One"},{"issue":"3","key":"10.1053\/j.ajkd.2016.04.011_bib27","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.cct.2005.01.010","article-title":"Sample sizes for clinical trials with time-to-event endpoints and competing risks","volume":"26","author":"Schulgen","year":"2005","journal-title":"Contemp Clin Trials"},{"issue":"8","key":"10.1053\/j.ajkd.2016.04.011_bib28","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1291\/hypres.29.597","article-title":"Plasma aldosterone in hypertensive patients on chronic hemodialysis: distribution, determinants and impact on survival","volume":"29","author":"Kohagura","year":"2006","journal-title":"Hypertens Res"},{"issue":"4","key":"10.1053\/j.ajkd.2016.04.011_bib29","first-page":"F257","article-title":"Extrarenal potassium homeostasis","volume":"240","author":"Bia","year":"1981","journal-title":"Am J Physiol"},{"issue":"3","key":"10.1053\/j.ajkd.2016.04.011_bib30","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/ndt\/gft515","article-title":"Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial","volume":"29","author":"Agarwal","year":"2014","journal-title":"Nephrol Dial Transplant"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027263861630107X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027263861630107X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:45:37Z","timestamp":1759459537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027263861630107X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S027263861630107X"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2016.04.011","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726403700.793520121","asserted-by":"object"}]},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2016.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}